Next Article in Journal
Early IgE Production Is Linked with Extrafollicular B- and T-Cell Activation in Low-Dose Allergy Model
Previous Article in Journal
Facilitators and Barriers to Take up a COVID-19 Vaccine Booster Dose among Community-Dwelling Older Adults in Hong Kong: A Population-Based Random Telephone Survey
Previous Article in Special Issue
ChAdOx1 nCoV-19 Immunogenicity and Immunological Response Following COVID-19 Infection in Patients Receiving Maintenance Hemodialysis
Article

BNT162b2 Booster Vaccination Induced Immunity against SARS-CoV-2 Variants among Hemodialysis Patients

1
The Felsenstein Medical Research Center, Nephrology Lab, Petah Tikva 4941492, Israel
2
Rabin Medical Center, Department of Nephrology, Petah Tikva 4941492, Israel
3
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel
4
Felsenstein Medical Research Center, Breast Cancer Research Lab, Petah Tikva 4941492, Israel
*
Author to whom correspondence should be addressed.
Academic Editor: Noa Berar Yanay
Vaccines 2022, 10(6), 967; https://doi.org/10.3390/vaccines10060967
Received: 9 May 2022 / Revised: 9 June 2022 / Accepted: 10 June 2022 / Published: 17 June 2022
Background: The emergence of new SARS-CoV-2 variants, which evade immunity, has raised the urgent need for multiple vaccine booster doses for vulnerable populations. In this study, we aimed to estimate the BNT162b2 booster effectiveness against the spread of coronavirus variants in a hemodialysis population. Methods: We compared humoral and cell-mediated immunity in 100 dialysis patients and 66 age-matched volunteers, before and 2–3 weeks following the first booster vaccine dose. Participants were assessed for anti-spike (RBD) antibody titer, neutralizing antibodies against B.1.617.2 (Delta) and B.1.1.529 (Omicron) variants, spike-specific T-cell responses by FACS and infection outbreak after the first and second booster. Results: Anti-spike antibody titer was significantly increased following the booster, with reduced humoral and cellular response in the dialysis patients. Neutralizing antibody levels increased significantly after the booster dose, with an inferior effect (≤2 fold) against Omicron compared with the Delta variant. Furthermore, CD4+ and CD8+ T-cell activation by Delta spike protein was preserved in 70% of PBMCs from the dialysis patients. A second booster dose tended to reduce breakthrough infections in the dialysis patients. Conclusions: Until the release of an updated vaccine, BNT162b2 booster doses will improve the humoral and cell-mediated immunity against variants. These findings support the importance of repetitive booster doses for hemodialysis patients. View Full-Text
Keywords: COVID-19 vaccine; hemodialysis patients; COVID-19 variants: B.1.617.2 (Delta) and B.1.1.529 (Omicron) COVID-19 vaccine; hemodialysis patients; COVID-19 variants: B.1.617.2 (Delta) and B.1.1.529 (Omicron)
Show Figures

Figure 1

MDPI and ACS Style

Herman-Edelstein, M.; Ben-Dor, N.; Agur, T.; Guetta, T.; Raiter, A.; Meisel, E.; Alkeesh, W.; Ori, Y.; Rozen-Zvi, B.; Zingerman, B. BNT162b2 Booster Vaccination Induced Immunity against SARS-CoV-2 Variants among Hemodialysis Patients. Vaccines 2022, 10, 967. https://doi.org/10.3390/vaccines10060967

AMA Style

Herman-Edelstein M, Ben-Dor N, Agur T, Guetta T, Raiter A, Meisel E, Alkeesh W, Ori Y, Rozen-Zvi B, Zingerman B. BNT162b2 Booster Vaccination Induced Immunity against SARS-CoV-2 Variants among Hemodialysis Patients. Vaccines. 2022; 10(6):967. https://doi.org/10.3390/vaccines10060967

Chicago/Turabian Style

Herman-Edelstein, Michal, Naomi Ben-Dor, Timna Agur, Tali Guetta, Annat Raiter, Eshcar Meisel, Weaam Alkeesh, Yaacov Ori, Benaya Rozen-Zvi, and Boris Zingerman. 2022. "BNT162b2 Booster Vaccination Induced Immunity against SARS-CoV-2 Variants among Hemodialysis Patients" Vaccines 10, no. 6: 967. https://doi.org/10.3390/vaccines10060967

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop